Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP: 1.Guiding Patients Through Advanced BTC Prognosis and Expectations

EP: 2.The Importance of Early Biomarker Testing in Managing Advanced BTC

EP: 3.Biomarker Testing in BTC: Approaches and Practices Across Academic and Community Clinicians

EP: 4.Expert Insights: Challenges With ctDNA Testing in BTC

EP: 5.Landmark Trials in First-Line Treatment Landscape for Advanced BTC: Expert Insights from TOPAZ-1 and KEYNOTE-966 Trials

EP: 6.Applying Data to Clinical Practice: Immunotherapy in the First-Line Treatment Setting in Advanced BTC

EP: 7.Understanding HER2 Testing in BTC: Detection and Clinical Approaches

EP: 8.Expert Perspectives From DESTINY-PanTumor 02 and Real-World Experience with Trastuzumab Deruxtecan in HER2-Positive BTC

EP: 9.New Approvals in HER2-Positive BTC: Zanidatamab - Key Findings from HERIZON-BTC-01 Study

EP: 10.Expert Perspectives in HER2-Positive BTC: Trastuzumab With Pertuzumab or Tucatinib From MyPathway and SGNTUC-019 Trials

Now Viewing

EP: 11.Clinical Insights: Incorporating Zanidatamab and Other HER2-Targeted Agents Into the Real-World Practice in Advanced BTC

EP: 12.Future Perspectives and Unmet Needs in HER2-Positive Advanced BTC Treatment

EP: 13.Key Takeaways From ASCO GI 2025: Exciting Updates on BTC

Video content above is prompted by the following:

• What is your general treatment approach when deciding among the available HER2-targeted agents? For those with HER2-positive tumors, are there situations in which you may still proceed with a 5-FU–containing regimen such as FOLFOX?
• Please comment on any differences and/or similarities in practice regarding HER2-directed therapy selection. Please describe any specific patient and/or disease factors considerations in your treatment approach.